The Latest Breaking News from Prescription Drug

Under the deal, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations.

The Centers for Medicare Medicaid Services (CMS) announced on Friday that Medicare Advantage (MA) and Medicare Part D prescription drug program premiums, benefits and plan options are expected to remain largely stable in 2026.

Most Medicare users know about deductibles and copays, but fewer realize that Part D prescription drug plans come with several hidden caps that can quietly...

How will Trump's tariffs impact prescription drugs in the U.S.? Let's find out.

For years, prescription drug costs have been one of the biggest financial burdens for seniors. Medicare reforms rolling out in 2025 aim to fix part...

Prescription drug costs weigh heavily on retirees’ budgets. Medicare Part D offers relief, but choosing the wrong plan can waste hundreds—or even thousands—each year. The...

Prescription drug costs remain one of the biggest worries for retirees. Medicare Part D was designed to help, but the program is full of choices...

The Trump administration is urging public health agencies to prioritize investigations of vaccine injuries, prescription drug use, and the cause of autism

Billionaire entrepreneur Mark Cuban, in a series of posts on the social media platform X early Monday morning, launched a scathing critique of the U.S. prescription drug industry, accusing large wholesalers and Pharmacy Benefit Managers (PBMs) of creating a “stranglehold” on pricing through opaque, anti-competitive practices.

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) supplemental New Drug Application (sNDA) of Pyrukynd (mitapivat) for adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025. 

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5.